Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis

The identification of KRASG12C inhibitors has reignited interest in targeting RAS proteins. This work describes the discovery of the KRASG12D-specific inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively targeting this oncogenic variant. MRTX1133 treatment markedly inhibited KRAS-dependent signaling and induced tumor regression in xenograft models harboring the KRASG12D mutation.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: MRTX1133 potently inhibits both the active state and the inactive state of KRASG12D and has anti-cancer activity in KRASG12D-bearing human tumor xenograft models.

References

  1. Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989). A review article that provides an overview of RAS family gene mutations and links to oncogenesis.

    CAS  PubMed  Google Scholar 

  2. Fernandez-Medarde, A. & Santos, E. Ras in cancer and development diseases. Genes Cancer 2, 344–358 (2011). A review article that summarizes the contributions of RAS mutations and altered RAS signaling to carcinogenesis.

    Article  CAS  Google Scholar 

  3. Ostrem, J. M. & Shokat, K. M. K-RasG12C inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013). A report that describes the structure-based validation of an allosteric regulatory site on KRASG12C that was found to be selectively targetable.

    Article  CAS  Google Scholar 

  4. Wang, X. & Marx, M. A. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J. Med. Chem. 65, 3123–3133 (2022). The structure-based discovery and characterization of MRTX1133.

    Article  CAS  Google Scholar 

  5. Hallin, J. & Christensen, J. G. The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers in mouse models and patients. Cancer Discov. 10, 54–71 (2020). The functional evaluation and characterization of MRTX849, including patient data, illustration of resistance mechanisms, and identification of potentially effective treatment combinations.

    Article  CAS  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat. Med. https://doi.org/10.1038/s41591-022-02007-7 (2022).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis. Nat Med 28, 2017–2018 (2022). https://doi.org/10.1038/s41591-022-02008-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-02008-6

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer